VCAM-1 Modulation for Cognitive Decline in Aging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Aging leads to structural and neurophysiological changes in the nervous system, resulting in cognitive decline and increased susceptibility to degenerative disorders, with synapse loss being a common pathological event in both normal aging and neurodegenerative conditions, posing a significant risk for dementia-related diseases like Alzheimer's.
Innovation Solution
Reducing cell surface VCAM-1 activity in mammals to treat aging-associated impairments, including cognitive impairments, by administering effective amounts of VCAM-1 specific binding members or modulating VCAM-1 activity to diminish its adhesion-mediated effects on endothelial cells and neurons.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If VCAM-1 activity is reduced to treat aging-associated impairments, then cognitive function is improved and neurogenesis is enhanced, but the mechanism involves targeting cell surface adhesion molecules which may affect other physiological processes
Solution Approach 1:
The patent uses VCAM-1 as a specific target molecule on endothelial cells as an intermediary to mediate the treatment effect. By targeting VCAM-1 activity, the invention indirectly influences neurogenesis and cognitive function without directly manipulating complex neural circuits, thereby simplifying the intervention mechanism while maintaining therapeutic efficacy.
Solution Approach 2:
The invention changes the activity level of VCAM-1 as a key parameter to achieve therapeutic effects. By modulating VCAM-1 activity (reducing it to treat aging-associated impairments), the patent creates a controllable parameter that links endothelial cell function to neural outcomes, enabling precise control over the treatment mechanism.
2Object-affected harmful factors
If VCAM-1 specific binding members are administered to reduce VCAM-1 activity, then adhesion-mediated effects on endothelial cells and neurons are diminished, but the specificity and potential off-target effects must be carefully managed
Solution Approach 1:
VCAM-1 serves as a specific intermediary target that mediates the interaction between endothelial cells and neurons. By focusing on VCAM-1 as the binding target, the invention achieves specific modulation of adhesion-mediated effects while using VCAM-1 itself as the precise measurement and control point for therapeutic action.
Solution Approach 2:
The patent leverages the multi-functional role of VCAM-1 in both endothelial cell adhesion and neural processes. A single VCAM-1 targeting approach can simultaneously address multiple harmful adhesion-mediated effects across different cell types and physiological contexts, improving efficiency while maintaining specificity through the universal VCAM-1 target.
Data Source
AI summary
Methods of treating an adult mammal for an aging-associated impairment are provided. Aspects of the methods include reducing cell surface VCAM-1 activity in the mammal in a manner sufficient to treat the mammal for the aging-associated impairment. A variety of aging-associated impairments may be treated by practice of the methods, which impairments include cognitive impairments.